The specter of generic challenges has long loomed around copyright’s iconic drug, Sildenafil, triggering questions about the prospects Pharma of connected medicinal ventures. While initial times saw substantial profits, the intellectual property lapse has allowed the way for cheaper substitutes, likely diminishing earnings and creating a real dan